Tetraphase antibiotic may reach up to $700 million in annual sales: CEO

NEW YORK (Reuters) - Tetraphase Pharmaceuticals Inc Chief Executive Guy Macdonald said annual sales of the company's lead experimental antibiotic for serious bacterial infections could climb as high as $700 million if approved.